La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Gulf Pharmaceutical Industries P.S.C Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Basel Nimer Ziyadeh

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.7yrs
Proprietà del CEO	n/a
Durata media del management	3.5yrs
Durata media del Consiglio di amministrazione	4.6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Jan 15

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Nov 04

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Mar 26

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

Feb 08

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

Dec 14

AMMINISTRATORE DELEGATO

Basel Nimer Ziyadeh

1.7yrs

Mandato

Mr. Basel Nimer Ali Ziyadeh is Chief Executive Officer of Gulf Pharmaceutical Industries P.S.C. from February 2023. Mr. Basel was CEO for Tabuk Pharmaceuticals, where he was instrumental in transforming th...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Basel Nimer Ziyadeh	Chief Executive Officer	1.7yrs	Nessun dato	Nessun dato
Ignacio Anglada	Chief Financial Officer	2.2yrs	Nessun dato	Nessun dato
Malik Metahri	Chief Technical Officer	1.8yrs	Nessun dato	Nessun dato
Adel Khalaf	General Counsel & Chief Compliance Officer	4.8yrs	Nessun dato	Nessun dato
Hosam Badr	Marketing Director	10.6yrs	Nessun dato	Nessun dato
Juergen Lauterbach	Chief Corporate Development & Strategy Officer	2.2yrs	Nessun dato	Nessun dato
Gopa Kumar	Chief Human Resources Officer	4.8yrs	Nessun dato	Nessun dato
Amgad Thabet	Chief Commercial Officer	4.8yrs	Nessun dato	Nessun dato
Rayan Omer	Company Secretary	no data	Nessun dato	Nessun dato

3.5yrs

Durata media

Gestione esperta: Il team dirigenziale di JULPHAR è considerato esperto (durata media dell'incarico 3.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Abdulaziz Al Zaabi	Director	7.8yrs	Nessun dato	Nessun dato
Rabih Khouri	Vice-Chairman of the Board	3.2yrs	Nessun dato	Nessun dato
Raman Garg	Independent Director	4.6yrs	Nessun dato	Nessun dato
Jean Diab	Director	1.5yrs	Nessun dato	Nessun dato
Saqer Bin Al Qassimi	Chairman of the Board	19.8yrs	Nessun dato	Nessun dato
Medhat Mohamed Al Gamal	Director	5.8yrs	Nessun dato	Nessun dato
Abboud Bejjani	Director	4.8yrs	Nessun dato	Nessun dato
Olfa Gam	Director	3.2yrs	Nessun dato	Nessun dato
Hamodi Abas Al limy	Director	2.3yrs	Nessun dato	Nessun dato

4.6yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di JULPHAR sono considerati esperti (durata media dell'incarico 4.4 anni).

Gulf Pharmaceutical Industries P.S.C Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Gulf Pharmaceutical Industries P.S.C., Annual General Meeting, Apr 22, 2024

Gulf Pharmaceutical Industries P.S.C. Announces Chief Executive Officer Changes

Less than half of directors are independent

Gulf Pharmaceutical Industries P.S.C. Announces Resignation of Sanjay Deshmukh as Chief Operating Officer

Less than half of directors are independent

Recent updates

Second quarter 2024 earnings released

Gulf Pharmaceutical Industries P.S.C. to Report Q2, 2024 Results on Aug 14, 2024

Now 21% overvalued

First quarter 2024 earnings released: EPS: د.إ0.002 (vs د.إ0.003 loss in 1Q 2023)

Gulf Pharmaceutical Industries P.S.C., Annual General Meeting, Apr 22, 2024

Full year 2023 earnings released: د.إ0.09 loss per share (vs د.إ0.029 loss in FY 2022)

Full year 2023 earnings released: د.إ0.087 loss per share (vs د.إ0.029 loss in FY 2022)

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Third quarter 2023 earnings released: د.إ0.034 loss per share (vs د.إ0.003 profit in 3Q 2022)

Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking

Second quarter 2023 earnings released: د.إ0.037 loss per share (vs د.إ0.003 profit in 2Q 2022)

First quarter 2023 earnings released

Full year 2022 earnings: EPS and revenues miss analyst expectations

Gulf Pharmaceutical Industries P.S.C. Announces Chief Executive Officer Changes

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: د.إ0.003 (vs د.إ0.028 in 3Q 2021)

Gulf Pharmaceutical Industries P.S.C. to Report Q3, 2022 Results on Nov 09, 2022

Gulf Pharmaceutical Industries P.S.C. Announces Resignation of Sanjay Deshmukh as Chief Operating Officer

Second quarter 2022 earnings released: EPS: د.إ0.003 (vs د.إ0.059 in 2Q 2021)

First quarter 2022 earnings: Revenues miss analyst expectations

Gulf Pharmaceutical Industries P.S.C. to Report Q1, 2022 Results on May 13, 2022

Price target decreased to د.إ1.57

Less than half of directors are independent

Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals

Third quarter 2021 earnings released: EPS د.إ0.028 (vs د.إ0.003 loss in 3Q 2020)

GlobalOne Healthcare acquired Gulf Inject LLC from Gulf Pharmaceutical Industries P.S.C.

Second quarter 2021 earnings released: EPS د.إ0.059 (vs د.إ0.028 loss in 2Q 2020)

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) completed the acquisition of remaining 60% stake in Planet Pharmacies LLC from KAMCO Investment Company K.S.C.P. (KWSE:KAMCO) and others.

An unknown buyer agreed to acquire 51% stake in Alpha Pharma L.L.C. from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR).

Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) agreed to acquire a 60% stake in Planet Pharmacies LLC.

First quarter 2021 earnings released: د.إ0.026 loss per share (vs د.إ0.094 loss in 1Q 2020)

Full year 2020 earnings released: د.إ0.28 loss per share (vs د.إ0.75 loss in FY 2019)

New 90-day low: د.إ1.26

Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.

New 90-day high: د.إ1.55

Radiant Pharmaceuticals Limited acquired Julphar Bangladesh Ltd from Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) and RAK Pharmaceuticals Pvt. Ltd. for BDT 1.4 billion.

Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like

New 90-day high: د.إ1.50

Third quarter 2020 earnings released: د.إ0.015 loss per share

New 90-day high: د.إ1.49

New 90-day high: د.إ1.35

Earnings released

Gulf Pharmaceutical Industries P.S.C. has completed a Follow-on Equity Offering in the amount of AED 500 million.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media